VBWG - Resource Item

Resources

Quick Order
About Create Profile Login
Email: Password:

Slide Lecture Programs
2004 Core Curriculum cash advance cash advance
Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section I: Atrial fibrillation, anticoagulation, and stroke prevention cash advance cash advance
April 16, 2004
Table of Contents - 66 slides
No.	Title
1	Nonvalvular AF: Issues and challenges cash advance cash advance
2	ATRIA: Prevalence of AF by age and sex cash advance cash advance
3	ATRIA: Projected number of patients with AF cash advance cash advance
4	Hospitalizations for AF are increasing cash advance cash advance
5	Mortality and AF cash advance cash advance
6	Embolic stroke cash advance cash advance
7	Stroke risk is increased in AF cash advance cash advance
8	Severity of stroke with AF cash advance cash advance
9	Framingham risk score: Relation to 5-year stroke risk cash advance cash advance
10	Framingham risk score: Relation to 5-year risk of stroke/death cash advance cash advance
11	Impact of selected AF risk factors on predicted 5-year risk of stroke/death cash advance cash advance
12	LV systolic dysfunction on echocardiography predicts stroke in AF patients cash advance cash advance
13	SPAF III: Stroke/systemic embolism event rates according to TEE findings cash advance cash advance
14	Prothrombotic states in AF cash advance cash advance
15	Potential prothrombotic mechanisms in AF: ↓ NO production cash advance cash advance
16	Potential prothrombotic mechanisms in AF: LAA stasis cash advance cash advance
17	Stroke mechanisms in AF: Proposed unifying model cash advance cash advance
18	Effect of anticoagulation intensity on post-stroke survival in patients with AF cash advance cash advance
19	AFFIRM: Effect of anticoagulation intensity on stroke risk cash advance cash advance
20	ACC/AHA/ESC guidelines for AF management: Newly discovered AF cash advance cash advance
21	ACC/AHA/ESC guidelines for AF management: Recurrent paroxysmal AF cash advance cash advance
22	ACC/AHA/ESC guidelines for AF management: Recurrent persistent and permanent AF cash advance cash advance
23	Warfarin in AF: Stroke risk reductions cash advance cash advance
24	Aspirin in AF: Stroke risk reductions cash advance cash advance
25	Oral anticoagulants vs aspirin for stroke prevention in AF cash advance cash advance
26	Coagulation cascade cash advance cash advance
27	Anticoagulant action of warfarin: Slow onset cash advance cash advance
28	Warfarin: Narrow therapeutic window cash advance cash advance
29	Limitations of warfarin cash advance cash advance
30	Warfarin limitations lead to under-treatment of AF cash advance cash advance
31	The ideal oral anticoagulant cash advance cash advance
32	Rationale for direct thrombin inhibition: A new anticoagulant strategy cash advance cash advance
33	Prothrombotic effects of thrombin cash advance cash advance
34	Coagulation cascade: Central role of thrombin cash advance cash advance
35	Thrombin binding sites cash advance cash advance
36	Direct thrombin inhibitor specificity for the active site cash advance cash advance
37	Heparins and direct thrombin inhibitors: Mechanisms of action cash advance cash advance
38	Direct thrombin inhibitors block both circulating and clot-bound thrombin cash advance cash advance
39	Characteristics of direct thrombin inhibitors cash advance cash advance
40	Direct thrombin inhibitors cash advance cash advance
41	Ximelagatran pharmacokinetics cash advance cash advance
42	Benefits of ximelagatran cash advance cash advance
43	SPORTIF III and V: Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation cash advance cash advance
44	SPORTIF III and V: Objective and design cash advance cash advance
45	SPORTIF III and V: Non-inferiority testing cash advance cash advance
46	SPORTIF III and V: Inclusion criteria cash advance cash advance
47	SPORTIF III: Quality of warfarin control cash advance cash advance
48	SPORTIF III: Primary outcome (stroke and systemic embolism) Intention-to-treat analysis cash advance cash advance
49	SPORTIF III: Primary outcome (stroke and systemic embolism) On-treatment analysis cash advance cash advance
50	SPORTIF III: Event rate comparisons for secondary composite outcomes cash advance cash advance
51	SPORTIF III: Incidence of hemorrhage cash advance cash advance
52	SPORTIF III: Incidence of liver enzyme elevation cash advance cash advance
53	SPORTIF III: Net clinical benefit cash advance cash advance
54	SPORTIF V: Quality of warfarin control cash advance cash advance
55	SPORTIF V: Primary outcome (stroke and systemic embolism) Intention-to-treat analysis cash advance cash advance
56	SPORTIF V: Primary and sensitivity analyses cash advance cash advance
57	SPORTIF V: Incidence of hemorrhage cash advance cash advance
58	SPORTIF V: Incidence of liver enzyme elevation cash advance cash advance
59	SPORTIF III and V pooled results: Primary outcome cash advance cash advance
60	SPORTIF III and V pooled results: Incidence of major bleeding cash advance cash advance
61	SPORTIF III and V pooled results: Net clinical benefit cash advance cash advance
62	SPORTIF III and V: Conclusions cash advance cash advance
63	THRIVE III: Extended secondary prevention of VTE with ximelagatran cash advance cash advance
64	THRIVE III: Incidence of hemorrhage cash advance cash advance
65	THRIVE III: Time course of liver enzyme elevation cash advance cash advance
66	THRIVE III: Conclusions cash advance cash advance


Home \| Literature Update \| Journal Link \| Resources \| Meeting Highlights \| Members \| About VBWG \| Web Links